• Vk
  • LinkedIn
  • Youtube
X7 Research
  • News
  • Registration strategy and Сonsulting
    • Budgeting
    • Registration strategy development
    • Study feasibility
    • Vendor selection
    • Data search and analysis
  • Clinical trials
    • Outsourcing CRAs in Russia and the EAEU
    • Development of medical documentation and biostatistics
    • Monitoring
    • Data-management
    • Patient home visits
    • Bioequivalence study
    • Therapeutic equivalence studies
    • Clinical trials of medical devices
  • Registration
    • Audit of the registration dossier
    • Bringing the registration dossier in compliance with the requirements of the EAEU
    • Conversion of registration dossier into XML format
    • PIL readability user testing
    • Translation of the Registration dossier
    • Turnkey registration
  • Post-authorization clinical studies
    • Phase IV studies
    • Non-interventional studies
    • Investigator-initiated studies
    • Post-authorisation safety study
    • Marketing research
  • Pharmacovigilance
    • QPPV in the EAEU
    • Safety monitoring of medical devices
    • Building a pharmacovigilance system
    • Safety in clinical trials
    • Pharmacovigilance audit
    • Pharmacovigilance contact person
  • Therapeutic expertise
    • Clinical trials in Oncology in the EAEU
  • Contact
  • EnglishEnglish
  • Menu

The share of Indian pharmaceutical companies account for 39% of the total number of FDA approvals

29.10.2018/in News /by Evgeniy Makarevich

India holds an important place in the global pharmaceutical sector. Indian R & D-oriented pharmaceutical companies and their subsidiaries received a large number of approved applications for the Abbreviated New Drug Application (ANDA) from the US Food and Drug Administration (FDA).

According to the Pharmabiz study, in the first half of the year (including June 2018), Indian pharmaceutical companies and their subsidiaries received 125 final ANDA approvals out of a total of 323 approvals. Thus, Indian companies accounted for about 39% of the total number of allegations. Similarly, these companies received 22 preliminary approvals (tentative approvals) out of a total of 71 provided by the FDA for this period.

In the first half of 2018, the level of approval was slightly lower compared to the same period in 2017, when the FDA approved a total of 387 applications and issued 85 preliminary approvals. Of these, 137 ANDA statements and 32 preliminary approvals were received by Indian companies.

According to the Pharmabiz study, Aurobindo Pharma is the leader among Indian companies, having received 22 ANDA endorsements. It is followed by Zydus Pharma – 16 approvals, Strides Shasun – 12, Cipla – 11. Lupin, Sun Pharma Global and Taro Pharma also received 8 statements each. This is followed by Dr. Reddy’s Laboratories and Glenmark Pharmaceuticals, each of which received 7 approvals in the first half of 2018. In addition, Aurobindo Pharma also became the leader in the number of preliminary approvals during the first half of this year.

During the 2017-2018 fiscal year, R & D expenses of Aurobindo increased to 91 million dollars. US and accounted for 4% of the company’s revenues (2.248 billion dollars), while sales in the United States increased to 1014 million dollars. in 2018, Lupin, India’s third largest pharmaceutical giant, incurred R & D costs of $ 252 million. during 2017–2018, which corresponds to 11.9% of sales. Dr. Reddy’s Laboratories spent $ 249 million on R & D. in 2017–2018 compared to 266 million dollars. for the previous year, which is 7% less.

Despite fierce competition, Indian pharmaceutical companies continue to grow rapidly. But, according to a Pharmabiz study, there is also a tendency to reduce the cost of R & D by some large companies, which may adversely affect the high rating indicators of Indian companies relative to ANDA. According to analysts, these companies should reverse the trend and invest more in R & D.

Link: gmpnews.ru

Share this entry
  • Share on Twitter
  • Share on WhatsApp
  • Share on Pinterest
  • Share on LinkedIn
  • Share on Tumblr
  • Share on Vk
  • Share on Reddit
  • Share by Mail

YOU MAY ALSO BE INTERESTED IN

Publications
Readability User Testing of Package Information Leaflets (PIL) in EAEU
Read More
Publications
Remote clinical trial monitoring
Read More
Publications
Post-authorization studies of drug safety in Russia
Read More

RUBRICS

Registration strategy and Сonsulting

Clinical trials

Registration

Post-authorization clinical studies

Pharmacovigilance

LATEST PUBLICATIONS

  • Corrections to clinical trial documents due to COVID-19. Russian experience.
  • WHAT IS BIOEQUIVALENCE
  • THE VOLUME OF RUSSIAN PHARMACEUTICAL MARKET 2016-2019

Tags

bioequivalenceClinical trials in the CISfeasibilitymonitoringRadiopharmaceuticals

CONTACT

0 + 1 = ?

This contact form is deactivated because you refused to accept Google reCaptcha service which is necessary to validate any messages sent by the form.

PRIVACY

Use of this site constitutes your consent to our Privacy Policy.


SOCIAL RESPONSIBILITY

X7 Research’s primary responsibility is to help our clients in bringing medicines & products to the market efficiently and safely.

The Best CRO for Clinical Trials | Full-service Global CRO — X7 Research

The Best CRO in Pharma | Clinical Research Organisation — X7 Research

The Best Contract Research Organisation (CRO) | Trusted CRO — X7 Research

The Best Clinical Research Organisation (CRO): Full Service CRO | X7 Research

The Best CRO in Research | Trusted CRO for Your Trail — X7 Research

The Best Clinical Trial Company | Global Full-service CRO - X7 Research

The Best Pharma CROs: Clinical Trials for Drugs | X7 Research

The Best CROs Company: Clinical Trials with Global CRO — X7 Research

The Best Pre-clinical CRO: Safety Assessment With X7 Research

The Best Clinical Development | Trusted CRO for Your Product: X7 Research

The Best Biostatistical Consulting: Statistical Services | X7 Research

The Best Pharmacovigilance Consulting Services | CRO — X7 Research

Feasibility in Clinical Trials: What is a Feasibility in Clinical Trials?

Clinical Study Trials: What are Clinical Study Trials?

Category
Strategy and consulting
Clinical trials
Registration
Post-authorization clinical studies
Pharmacovigilance

Registration strategy and Сonsulting
Registration strategy development
Budgeting
Study feasibility
Vendor selection
Data search and analysis

Clinical trials
Development of medical documentation and biostatistics
Monitoring
Data management
Patient home visits
Bioequivalence study
Therapeutic equivalence studies

Registration
Audit of the registration dossier
Dossier eaeu
Conversion of registration dossier into xml format
Pil readability user testing
Turnkey registration

Post-authorization clinical studies
Phase iv studies
Non interventional studies
Investigator initiated studies
Post authorisation safety study
Marketing research

Pharmacovigilance
Building a pharmacovigilance system
Safety in clinical trials
Pharmacovigilance audit
Pharmacovigilance contact person

Blog
Contacts

© Copyright 2010-2023 - X7 Research. All rights reserved.
What do people know about clinical trials? Amgen reduced the cost of evolocumab in the US by 60%
Scroll to top